(ATAI) ATAI Life Sciences BV - Overview

Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 1.478m USD | Total Return: 113.9% in 12m

Psychedelics, Mental Health Drugs, Biopharmaceuticals, Neuromodulators
Total Rating 36
Safety 25
Buy Signal -0.40
Biotechnology
Industry Rotation: -8.2
Market Cap: 1.48B
Avg Turnover: 17.4M
Risk 3d forecast
Volatility76.9%
VaR 5th Pctl11.6%
VaR vs Median-8.40%
Reward TTM
Sharpe Ratio1.28
Rel. Str. IBD76.5
Rel. Str. Peer Group49.3
Character TTM
Beta1.514
Beta Downside2.045
Hurst Exponent0.458
Drawdowns 3y
Max DD59.23%
CAGR/Max DD0.59
CAGR/Mean DD1.11
EPS (Earnings per Share) EPS (Earnings per Share) of ATAI over the last years for every Quarter: "2021-03": -0.57, "2021-06": -0.37, "2021-09": -0.21, "2021-12": -0.62, "2022-03": -0.24, "2022-06": -0.24, "2022-09": -0.22, "2022-12": -0.28, "2023-03": -0.21, "2023-06": -0.21, "2023-09": -0.28, "2023-12": -0.12, "2024-03": -0.17, "2024-06": -0.36, "2024-09": -0.16, "2024-12": -0.24, "2025-03": -0.15, "2025-06": -0.14, "2025-09": -0.28, "2025-12": -1.73, "2026-03": -0.0833,
Last SUE: 0.03
Qual. Beats: 0
Revenue Revenue of ATAI over the last years for every Quarter: 2021-03: 19.88, 2021-06: 0, 2021-09: 0.266, 2021-12: 0.23, 2022-03: 0, 2022-06: 0.17, 2022-09: 0.024, 2022-12: 0.038, 2023-03: 0.037, 2023-06: 0.172, 2023-09: 0.087, 2023-12: 0.018, 2024-03: 0, 2024-06: 0.273, 2024-09: 0.04, 2024-12: -0.005, 2025-03: 1.555, 2025-06: 0.719, 2025-09: 0.749, 2025-12: 1.066, 2026-03: 0.953999,
Rev. CAGR: 213.97%
Rev. Trend: 89.5%
Last SUE: 1.42
Qual. Beats: 5

Warnings

Share dilution 102.8% YoY

Interest Coverage Ratio -2496.9 is critical

Altman Z'' -15.00 < 1.0 - financial distress zone

Volatile

Tailwinds

No distinct edge detected

Description: ATAI ATAI Life Sciences BV

ATAI Life Sciences (ATAI) is a clinical-stage biopharmaceutical company focused on developing therapies for mental health disorders, including treatment-resistant depression, schizophrenia-related cognitive impairment, and social anxiety. The company’s pipeline utilizes diverse delivery methods such as intranasal formulations, oral transmucosal films, and pro-cognitive neuromodulators to target unmet needs in psychiatry.

The company operates under a decentralized drug development model, acquiring and managing programs through various subsidiaries to diversify clinical risk across multiple therapeutic candidates. This approach is common in the biotechnology sector, where high R&D costs and regulatory hurdles necessitate a portfolio-based strategy to mitigate the impact of potential trial failures.

Current clinical assets include BPL-003 and VLS-01 for depression, alongside RL-007, which is currently undergoing Phase 2b trials for cognitive symptoms in schizophrenia. Investors may find it beneficial to monitor clinical data updates on ValueRay to better understand how these milestones affect the companys valuation.

Headlines to Watch Out For
  • Clinical trial data readouts for BPL-003 determine short-term valuation and investor confidence
  • Cash runway and burn rate dictate timing of future dilutive equity offerings
  • Regulatory shifts in psychedelic medicine scheduling impact long-term commercialization and market access
  • Strategic partnerships and milestone payments from COMP360 development drive non-dilutive capital inflows
  • Success of RL-007 Phase 2b trials influences expansion into broader neuropsychiatric markets
Piotroski VR-10 (Strict) 1.0
Net Income: -663.4m TTM > 0 and > 6% of Revenue
FCF/TA: -2.50 > 0.02 and ΔFCF/TA -185.8 > 1.0
NWC/Revenue: 6.45k% < 20% (prev 4.70k%; Δ 1.76k% < -1%)
CFO/TA -0.40 > 3% & CFO -106.6m > Net Income -663.4m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 10.02 > 1.5 & < 3
Outstanding Shares: last quarter (357.4m) vs 12m ago 102.8% < -2%
Gross Margin: 70.99% > 18% (prev -4.95%; Δ 7.59k% > 0.5%)
Asset Turnover: 1.51% > 50% (prev 0.95%; Δ 0.56% > 0%)
Interest Coverage Ratio: -2.50k > 6 (EBITDA TTM -663.2m / Interest Expense TTM 266k)
Altman Z'' -15.00
A: 0.85 (Total Current Assets 250.1m - Total Current Liabilities 25.0m) / Total Assets 264.9m
B: -5.25 (Retained Earnings -1.39b / Total Assets 264.9m)
C: -2.88 (EBIT TTM -664.2m / Avg Total Assets 230.3m)
D: -21.29 (Book Value of Equity -1.41b / Total Liabilities 66.1m)
Altman-Z'' = -53.26 = D
Beneish M -1.58
DSRI: 5.27 (Receivables 14.7m/1.49m, Revenue 3.49m/1.86m)
GMI: 1.00 (fallback, negative margins)
AQI: 0.11 (AQ_t 0.04 / AQ_t-1 0.38)
SGI: 1.87 (Revenue 3.49m / 1.86m)
TATA: -2.10 (NI -663.4m - CFO -106.6m) / TA 264.9m)
Beneish M = -1.58 (Cap -4..+1) = CCC
What is the price of ATAI shares?

As of May 24, 2026, the stock is trading at USD 4.32 with a total of 4,965,460 shares traded.
Over the past week, the price has changed by +7.60%, over one month by -8.28%, over three months by +8.82% and over the past year by +113.86%.

Is ATAI a buy, sell or hold?

ATAI Life Sciences BV has received a consensus analysts rating of 4.71. Therefore, it is recommended to buy ATAI.

  • StrongBuy: 5
  • Buy: 2
  • Hold: 0
  • Sell: 0
  • StrongSell: 0

What are the forecasts/targets for the ATAI price?
Analysts Target Price 14 224.1%
ATAI Life Sciences BV (ATAI) - Fundamental Data Overview as of 24 May 2026
P/S = 423.7928
P/B = 6.6645
Revenue TTM = 3.49m USD
EBIT TTM = -664.2m USD
EBITDA TTM = -663.2m USD
Long Term Debt = 1.69m USD (estimated: total debt 2.00m - short term 310k)
Short Term Debt = 310k USD (from shortTermDebt, last quarter)
Debt = 2.00m USD (from shortLongTermDebtTotal, last quarter) (leases 2.07m already included)
Net Debt = -198.7m USD (calculated: Debt 2.00m - CCE 200.7m)
Enterprise Value = 1.28b USD (1.48b + Debt 2.00m - CCE 200.7m)
Interest Coverage Ratio = -2.50k (Ebit TTM -664.2m / Interest Expense TTM 266k)
EV/FCF = -1.93x (Enterprise Value 1.28b / FCF TTM -662.2m)
FCF Yield = -51.76% (FCF TTM -662.2m / Enterprise Value 1.28b)
 FCF Margin = -19.0k% (FCF TTM -662.2m / Revenue TTM 3.49m)
 Net Margin = -19.0k% (Net Income TTM -663.4m / Revenue TTM 3.49m)
 Gross Margin = 70.99% ((Revenue TTM 3.49m - Cost of Revenue TTM 1.01m) / Revenue TTM)
Gross Margin QoQ = 82.49% (prev none%)
Tobins Q-Ratio = 4.83 (Enterprise Value 1.28b / Total Assets 264.9m)
Interest Expense / Debt = 13.30% (Interest Expense 266k / Debt 2.00m)
Taxrate = 21.0% (US default 21%)
NOPAT = -524.7m (EBIT -664.2m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 7.00 (Total Current Assets 250.1m / Total Current Liabilities 35.7m)
Debt / Equity = 0.01 (Debt 2.00m / totalStockholderEquity, last quarter 198.7m)
 Debt / EBITDA = 0.30 (negative EBITDA) (Net Debt -198.7m / EBITDA -663.2m)
 Debt / FCF = 0.30 (negative FCF - burning cash) (Net Debt -198.7m / FCF TTM -662.2m)
 Total Stockholder Equity = 181.0m (last 4 quarters mean from totalStockholderEquity)
 RoA = -288.0% (out of range, set to none)
 RoE = -42.23% (Net Income TTM -663.4m / Total Stockholder Equity 1.57b)
RoCE = -42.23% (EBIT -664.2m / Capital Employed (Equity 1.57b + L.T.Debt 1.69m))
 RoIC = -313.8% (out of range, set to none) (NOPAT -524.7m / Invested Capital 167.2m)
 WACC = 11.31% (E(1.48b)/V(1.48b) * Re(11.31%) + D(2.00m)/V(1.48b) * Rd(13.30%) * (1-Tc(0.21)))
Discount Rate = 11.31% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 91.11 | Cagr: 43.40%
 [DCF] Fair Price = unknown (Cash Flow -662.2m)
 EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.03 | # QB: 0
Revenue Correlation: 89.48 | Revenue CAGR: 214.0% | SUE: 1.42 | # QB: 5
EPS current Quarter (2026-06-30): EPS=-0.11 | Chg30d=+10.35% | Revisions=-14% | Analysts=9
EPS next Quarter (2026-09-30): EPS=-0.12 | Chg30d=+9.73% | Revisions=-33% | Analysts=9
EPS current Year (2026-12-31): EPS=-0.43 | Chg30d=+13.04% | Revisions=-33% | GrowthEPS=+85.2% | GrowthRev=-74.7%
EPS next Year (2027-12-31): EPS=-0.46 | Chg30d=+6.28% | Revisions=-43% | GrowthEPS=-5.3% | GrowthRev=-71.0%
[Analyst] Revisions Ratio: -43%